As a part of the agreement, MJFF will sponsor the study, owns and shares all the data and results generated by the trial. Further development plans will depend upon the results of the study.
Patient enrollment is expected to begin later this year for the trial, which will be conducted at clinical sites in the US.
MJFF chief executive officer Todd Sherer said: "AVE8112 has shown promising pro-cognitive activity in preclinical models that could be of interest to the under-addressed cognitive aspects of Parkinson’s disease, an area of unmet need where a new treatment could make a tangible difference in patients’ lives."
Sanofi Global R&D president Elias Zerhouni said: "Through this research collaboration, together we will be able to study Sanofi’s pharmaceutical compound for a possible new treatment for PD patients around the world."